PGT-A and Egg Donor IVF in Thailand: Is It Necessary?

Understanding PGT-A in Donor Egg IVF

When using donor eggs for IVF, you may wonder whether preimplantation genetic testing for aneuploidy (PGT-A) is necessary. PGT-A screens embryos for chromosomal abnormalities before transfer. However, because egg donors are typically young and healthy, the risk of chromosomal abnormalities is generally low. As a result, PGT-A is often not recommended for donor egg cycles. This guide explains the reasoning, situations where PGT-A might still be considered, and questions to ask your clinic.

At a Glance: Key Points

• PGT-A is a screening test, not a guarantee of pregnancy or a healthy baby.
• Young donors have lower aneuploidy rates, so PGT-A may add limited value.
• PGT-A may be considered in specific cases, such as advanced maternal age or previous miscarriages.
• Discuss the pros, cons, and costs with your fertility specialist.

What Is PGT-A and How Does It Work?

PGT-A (preimplantation genetic testing for aneuploidy) checks embryos for an abnormal number of chromosomes. Embryos with the correct number of chromosomes are called euploid; those with missing or extra chromosomes are aneuploid. Aneuploidy is a common cause of implantation failure and miscarriage.

In an IVF cycle, embryos are cultured for several days, and a small number of cells are biopsied. These cells are then analyzed using techniques like next-generation sequencing. Only embryos that appear euploid are considered for transfer.

It’s important to understand that PGT-A is a screening test. It cannot detect all genetic conditions, nor does it guarantee a successful pregnancy or a healthy baby.

Why PGT-A Is Often Not Recommended with Donor Eggs

Egg donors are usually in their twenties or early thirties, an age when aneuploidy rates are naturally low. For example, the risk of chromosomal abnormalities in embryos from young donors is significantly lower than in embryos from women over 35. Because of this, many fertility specialists believe that PGT-A adds little benefit in donor egg cycles.

Additionally, PGT-A involves embryo biopsy, which is an invasive procedure with a small risk of damaging the embryo. There is also the cost of the testing itself, which may not be covered by insurance. Given the low baseline risk, the potential benefits of PGT-A may not outweigh these drawbacks for most patients using donor eggs.

When PGT-A Might Still Be Considered

There are situations where PGT-A may be considered even with donor eggs. These include:

• Advanced maternal age of the recipient: While the donor’s age is the main factor in embryo aneuploidy, some clinics may consider PGT-A if the recipient is older, though evidence is limited.
• Previous miscarriages or failed IVF cycles: If you have experienced recurrent pregnancy loss or multiple failed transfers, PGT-A might help identify chromosomal issues as a cause.
• Balanced translocation in the donor or recipient: If either party carries a chromosomal rearrangement, PGT-A or PGT-SR may be recommended.
• Personal preference: Some patients prefer the additional information PGT-A provides, even if the medical necessity is unclear.

It’s essential to discuss your specific history and concerns with your fertility specialist to determine if PGT-A is appropriate for you.

Alternatives to PGT-A with Donor Eggs

If you decide not to pursue PGT-A, there are other ways to increase the chances of a successful donor egg cycle:

• Choosing a screened donor: Reputable clinics screen donors for genetic and infectious diseases, reducing the risk of inherited conditions.
• Optimizing your uterine health: A thorough evaluation of your uterine cavity and hormonal preparation can improve implantation.
• Transferring a single embryo: Elective single embryo transfer (eSET) reduces the risk of multiple pregnancy while maintaining good success rates.

These alternatives focus on overall cycle quality rather than embryo selection.

Questions to Ask Your Clinic About PGT-A

Before deciding on PGT-A, consider asking your clinic the following questions:

• What is the aneuploidy rate for embryos from donors of the age I’m considering?
• What are the success rates for donor egg cycles with and without PGT-A?
• What is the cost of PGT-A, and are there additional biopsy or shipping fees?
• How many embryos typically survive the biopsy and testing process?
• What are the risks of embryo biopsy?
• How will PGT-A results be used in my treatment plan?

These questions can help you make an informed decision based on your unique situation.

Next Steps: Making Your Decision

Deciding whether to use PGT-A with donor eggs is personal. Here’s a simple checklist to guide you:

1. Review your medical history and any previous pregnancy outcomes.
2. Discuss the potential benefits and limitations of PGT-A with your fertility specialist.
3. Ask for data on your clinic’s donor egg outcomes, both with and without PGT-A.
4. Consider the financial implications and whether the cost is justified for you.
5. Make a decision that aligns with your values and goals.

Remember, PGT-A is a tool, not a guarantee. Your fertility team can help you weigh the options.

Conclusion

In summary, PGT-A is often not necessary when using donor eggs in Thailand, because young donors have a low risk of chromosomal abnormalities. However, there are specific situations where it might be considered. By understanding the purpose and limitations of PGT-A, and by asking the right questions, you can make a confident choice for your family-building journey.

For more information on PGT in Thailand, visit our PGT in Thailand page. You can also explore our guides and FAQ sections for additional insights.

Frequently asked questions

Is PGT-A always recommended with donor eggs?

No, PGT-A is not always recommended with donor eggs. Because egg donors are typically young, the risk of chromosomal abnormalities is low, so many clinics do not advise PGT-A as a routine part of donor egg IVF. However, it may be considered in specific cases, such as previous miscarriages or if the donor is known to carry a chromosomal rearrangement.

What is the difference between PGT-A and PGT-M?

PGT-A screens embryos for an abnormal number of chromosomes (aneuploidy), while PGT-M is used to detect specific single-gene disorders, such as cystic fibrosis or sickle cell anemia. PGT-M is typically used when one or both parents are known carriers of a genetic condition.

Can PGT-A guarantee a successful pregnancy?

No, PGT-A cannot guarantee a successful pregnancy. It is a screening test that helps select embryos with the correct number of chromosomes, but it does not ensure implantation, a live birth, or a healthy baby. Other factors, such as uterine health and embryo quality, also play a role.

Does PGT-A harm the embryo?

PGT-A involves a biopsy of a few cells from the embryo, which carries a small risk of damaging the embryo. However, the procedure is generally considered safe, and most embryos survive the process. Your clinic can provide more details about the risks and benefits.

Continue your research

• PGT in Thailand overview
• PGT and IVF guides
• Frequently asked questions

Medical information notice: This article is educational and does not replace individual assessment, diagnosis, genetic counselling or treatment advice from a licensed clinician. Provider services, availability, fees and policies should be verified directly before booking.